Journal for ImmunoTherapy of Cancer

Published by: Biomed Central Ltd  

People

  1. Budhu
    Budhu
  2. Postow
    Postow
  3. Liu
    Liu
  4. Cheung
    Cheung
  5. Panageas
    Panageas
  6. Deng
    Deng
  7. Hirschhorn Cymerman
    Hirschhorn Cymerman
  8. Rudin
    Rudin
  9. Wong
    Wong
  10. Zhong
    Zhong

Groups

  1. GSK Faculty (121)
  2. Department of Medicine (107)
  3. Solid Tumor Oncology Division (96)
  4. Melanoma and Immunotherapeutics Service (83)
  5. Sloan Kettering Institute Postdocs (65)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (35)
  7. Hematologic Malignancies, Division of (33)
  8. Melanoma Disease Management Team (29)
  9. Sloan Kettering Institute Faculty (23)
  10. Tow Center for Developmental Oncology (TCDO) (22)
Search Within
  1. "GSK Faculty"
Formats
  1. Meeting Abstract (83)
  2. Journal Article (36)
  3. Guidelines (2)
Groups
  1. GSK Faculty (121)
  2. Department of Medicine (107)
  3. Solid Tumor Oncology Division (96)
  4. Melanoma and Immunotherapeutics Service (83)
  5. Sloan Kettering Institute Postdocs (65)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (35)

More Groups

People
  1. Jedd Wolchok (81)
  2. Taha Merghoub (48)
  3. Sadna Budhu (21)
  4. Michael Postow (18)
  5. Roberta Zappasodi (18)
  6. Cailian Liu (11)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (4)
  4. 2022 (19)
  5. 2021 (17)
  6. 2020 (13)

More Years

Publishers
  1. Biomed Central Ltd (121)

Results (121)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The cold immunological landscape of ATM-deficient cancers
    Journal Article

    Sinha, S.; Ng, V.; Novaj, A.; Zhu, Y.; Yazaki, S.; Pei, X.; Derakhshan, F.; Pareja, F.; Setton, J.; Naulin, F.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): Expansion cohorts and correlative analyses
    Journal Article

    Seligson, N. D.; Chen, J. L.; Goodrich, A. C.; Van Tine, B. A.; Campbell, J. D.; Richards, A. L.; Antonescu, C. R.; Liebner, D. A.; Milhem, M. M.; Streicher, H.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Developing a membrane-proximal CD33-targeting CAR T cell
    Journal Article

    Freeman, R.; Shahid, S.; Khan, A. G.; Mathew, S. C.; Souness, S.; Burns, E. R.; Um, J. S.; Tanaka, K.; Cai, W.; Yoo, S.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells
    Journal Article

    Yankelevich, M.; Thakur, A.; Modak, S.; Chu, R.; Taub, J.; Martin, A.; Schalk, D.; Schienshang, A.; Whitaker, S.; Rea, K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
    Journal Article

    Molvi, Z.; Klatt, M. G.; Dao, T.; Urraca, J.; Scheinberg, D. A.; O'Reilly, R. J.
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study
    Journal Article

    Elkrief, A.; Alessi, J. M. V.; Ricciuti, B.; Brown, S.; Rizvi, H.; Preeshagul, I. R.; Wang, X.; Pecci, F.; Di Federico, A.; Lamberti, G.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
    Journal Article

    Park, J. A.; Espinosa-Cotton, M.; Guo, H. F.; Monette, S.; Cheung, N. K. V.
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
    Journal Article

    Rudin, C. M.; Pandha, H. S.; Zibelman, M.; Akerley, W. L.; Harrington, K. J.; Day, D.; Hill, A. G.; O'Day, S. J.; Clay, T. D.; Wright, G. M.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Gut dysbiosis suppresses anti-tumor ILC2S in pancreatic cancer
    Meeting Abstract

    Zebboudj, A.; Amisaki, M.; Guasp, P.; Rojas, L.; Sethna, Z.; Theresa, W.; Chandra, A.; Yu, R.; Odgerel, Z.; Soares, K.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A novel humanized T cell-engaging CD24XCD3 bispecific antibody for CD24-positive solid tumors
    Meeting Abstract

    Espinosa-Cotton, M.; Guo, H. F.; Cheung, N. K.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save

    • Journal for ImmunoTherapy of Cancer – authorized name for:

    Name ISSN / ISBN Publisher
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Biomed Central Ltd
    Journal for Immunotherapy of Cancer BMJ Publishing Group Ltd.
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for Immunotherapy of Cancer BMJ Publishing Group Ltd.
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Author(s) (or Their Emp Oyer(s)) 2025
    Journal for ImmunoTherapy of Cancer 20511426 Unknown
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Author(s) (or Their Employer(s)) 2025
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 The Author(s)
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 BMJ Group
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for Immunotherapy of Cancer 2051-1426 Bmc
    Journal for ImmunoTherapy of Cancer 20511426 Author(s) (or Their Employer(s)) 2024
    Journal for ImmunoTherapy of Cancer 2017 Nov 8-12 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Bmj
    Journal for ImmunoTherapy of Cancer 2051-1426 Biomed Central Ltd
    Journal for ImmunoTherapy of Cancer 20511426 Author(s) (or Their Employer(s))
    Unknown (2051-1426) 2051-1426 Biomed Central Ltd